A Snap-N-Spike® reference solution applicable to use in clinical toxicology by LC-MS/MS or GC/MS. Metformin is an antidiabetic drug which functions by suppressing liver production of glucose. This biguanide analog is used specifically for treatment of type 2 diabetes.
법적 정보
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases
Archives of medical research, 31(6), 571-575 (2001-03-21)
Renal hyperfiltration and albuminuria have a deleterious effect on kidney function. Therefore, we studied the effect of metformin on blood pressure, renal hemodynamics, and microalbuminuria in type 2 diabetic patients. A clinical trial was designed in type 2 diabetic patients
Journal of internal medicine, 257(1), 100-109 (2004-12-21)
The UK Prospective Diabetes Study (UKPDS) showed that treatment with metformin decreases macrovascular morbidity and mortality independent of glycaemic control. We hypothesized that metformin may achieve this by improving endothelial function and chronic, low-grade inflammation. Data on this issue are
The Journal of clinical endocrinology and metabolism, 85(9), 3161-3168 (2000-09-22)
Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial. Oral contraceptive pills are commonly used in the
British journal of clinical pharmacology, 50(4), 325-332 (2000-09-30)
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. An open-label, three treatment, three period crossover study was conducted in 11